Tarsus Pharmaceuticals, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
CEO Bobak Azamian and CFO Jeffrey Farrow certified the Q2 2026 10-Q (period ended June 30, 2026) on August 6, 2026, attesting to the accuracy of financial statements and effectiveness of internal controls and disclosure procedures. No material weaknesses, significant deficiencies, or fraud were disclosed in the certifications.
Why this rating
Routine SOX compliance filing. No substantive business, financial, or operational changes disclosed; standard periodic certification requirement.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.